首页|系统性红斑狼疮药物研究进展

系统性红斑狼疮药物研究进展

Research Progress on Systemic Lupus Erythematosus Drugs

扫码查看
系统性红斑狼疮(Systemic Lupus Erythematosus,SLE)是一种系统性自身免疫疾病,患者血液中一般存在大量的自身抗体,并表现出多器官受累现象,该疾病发病进程缓慢且多易复发,严重威胁患者健康.目前,这种疾病的发病原因尚不明确,且没有任何已知的治愈方法,治疗目标以减缓疾病进展和缓解症状为主.本文通过丁香园Insight数据库对目前已上市及正在研究的SLE治疗药物进行了检索,并从药物研究所处阶段、药物研究靶点选择及药物成分分类 3 个维度对其进行了简要分析,以期为后续药物研究及临床治疗选择提供借鉴.
Systemic lupus erythematosus(SLE)is a systemic autoimmune disease,patients generally have a large number of autoantibodies in the blood,and show multi-organ involvement,the disease process is slow and easy to recur,seriously threatening the health of patient.At present,the cause of this disease is unknown,and there is no known cure,and the goal of treatment is to slow the progression of the disease and relieve symptoms.In this paper,SLE therapeutics currently on the market and under study are searched through the Lilac Garden Insight database,and briefly analyzed them from three dimensions:drug research institute stage,drug research target selection and drug component classification,in order to form a reference for follow-up drug research and clinical treatment selection.

systemic lupus erythematosusdrug progressiontarget

苏阳、马小涵

展开 >

石家庄高新技术产业开发区 科技创业园区技术市场管理中心,河北石家庄 050000

河北省自身免疫病药物研究重点实验室,河北石家庄 050000

河北菲尼斯生物技术有限公司,河北石家庄 050000

系统性红斑狼疮 药物进展 靶点

2024

生物化工

生物化工

ISSN:
年,卷(期):2024.10(1)
  • 20